Received Mar 26, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
He reported feeling the dose administered to be thick and extremely painful; His arm was very sore and the soreness lasted for 3 to 4 days; This non-serious case was reported by a non-health professional and described the occurrence of injection site pain in a 50-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix (unknown arm) .5 ml. On an unknown date, immediately after receiving Shingrix, the patient experienced injection site pain (Verbatim: He reported feeling the dose administered to be thick and extremely painful) and pain in arm (Verbatim: His arm was very sore and the soreness lasted for 3 to 4 days). The outcome of the injection site pain and pain in arm were resolved (duration 4 days). It was unknown if the reporter considered the injection site pain and pain in arm to be related to Shingrix. It was unknown if the company considered the injection site pain and pain in arm to be related to Shingrix. Additional Information: GSK Receipt Date: 16-MAR-2026 The reporter was a caregiver. The batch number was not provided upon follow-up with the reporter